Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus

Transplantation Proceedings

Volumn 42, Issue 10, 2010, Pages 4573-4577

  Van Der Laan, L J W ^a   Hudson, M ^b   McPherson, S ^b   Zondervan, P E ^a   Thomas, R C ^b   Kwekkeboom, J ^a   Lindsay, A S ^b   Burt, A D ^b   Kazemier, G ^a   Tilanus, H W ^a   Bassendine, M F ^b   Metselaar, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; TACROLIMUS;

ADULT; ANTIVIRAL THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 78650440246     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.10.013     Document Type: Conference Paper

References (50)

1. M. Berenguer, L. Ferrell, and J. Watson HCV-related fibrosis progression following liver transplantation: increase in recent years J Hepatol 32 2000 673
2. O. Chazouilleres, M. Kim, and C. Combs Quantitation of hepatitis C virus RNA in liver transplant recipients Gastroenterol 106 1994 994
3. M. Prieto, M. Berenguer, and J.M. Rayon High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250
4. C. Feray, L. Caccamo, and G.J. Alexander European Concerted Action on Viral Hepatitis (EUROHEP) Group: European collaborative study on factors influencing outcome after liver transplantation for hepatitis C Gastroenterology 117 1999 619
5. A. Snchez-Fueyo, J.C. Restrepo, and L. Qunit Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft Transplantation 73 2002 56
6. L.M. Forman, J.D. Lewis, and J.A. Berlin The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889
7. M. Charlton, E. Seaberg, and R. Wiesner Predictors of patient and graft survival following liver transplantation for hepatitis C Hepatology 28 1998 823
8. S. Iacob, V.R. Cicinnati, and P. Hilgard Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation Transplantation 84 2007 56
9. M. Berenguer, M. Prieto, and F. San Juan Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplantation recipients Hepatology 36 2002 202
10. M.R. Foxton, A. Quaglia, and P. Mueisan The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C Am J Transplant 6 2006 1922
11. S.C. Rayhill, Y.M. Wu, and D.A. Katz Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C Transplantation 84 2007 331
12. P. Ciccorossi, A.M. Maina, and F. Oliveri Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C Liver Int 27 2007 612
13. M. Wali, R.F. Harrison, and P.J. Gow Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C Gut 51 2002 248
14. B. Roche, and D. Samuel Risk factors for hepatitis C recurrence after liver transplantation J Viral Hepat 14 suppl 1 2007 89
15. M. Berenguer, J. Crippin, and R. Gish A model to predict severe HCV-related disease following liver transplantation Hepatology 38 2003 34
16. T.S. Lie, H. Preissinger, and M. Bach The protective effect of cyclosporine against cirrhotic alteration of the liver Surgery 110 1991 847
17. F. Villamil, G. Levy, and G.L. Grazi Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine Transplant Proc 38 2006 2964
18. M.W. Johnson, W.K. Washburn, and R.B. Freeman Hepatitis C viral infection in liver transplantation Arch Surg 131 1996 284
19. T. Walter, J. Dumortier, and O. Guillaud Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center Liver Transpl 13 2007 294
20. M. Berenguer, V. Aguilera, and M. Prieto Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients Liver Transpl 12 2006 762
21. P. Hilgard, A. Kahraman, and N. Lehmann Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis World J Gastroenterol 12 2006 697
22. J. Hunt, F.D. Gordon, and W.D. Lewis Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens Liver Transpl 7 2001 1056
23. S.W. Paik, H.P. Tan, and A.S. Klein Outcome of orthotopic liver transplantation in patients with hepatitis C Dig Dis Sci 47 2002 450
24. P. Martin, R.W. Busuttil, and R.M. Goldstein Impact of tacrolimus versus cyclosporine in hepatitis C virusinfected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial Liver Transplantation 10 2004 1258
25. K. Ishak, A. Baptista, and L. Bianchi Histological grading and staging of chronic hepatitis J Hepatol 22 1995 696
26. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C Hepatology 24 1996 289
27. G. Levy, F. Villamil, and D. Samuel Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation Transplantation 77 2004 1632
28. G. Levy, G.L. Grazi, and F. Sanjuan 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus Liver Transpl 12 2006 1464
29. R.J. Firpi, H. Zhu, and G. Morelli Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation Liver Transplantation 12 2006 51
30. N. Ishii, K. Watashi, and T. Hishiki Diverse effects of cyclosporine on hepatitis C virus strain replication J Virol 80 2006 4510
31. K. Watashi, M. Hijikata, and M. Hosaka Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282
32. K. Goto, K. Watashi, and T. Murata Evaluation of the antihepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811 Biochem Biophys Res Commun 343 2006 879
33. M.A. El-Farrash, H.H. Aly, and K. Watashi In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin Microbiol Immunol 51 2007 127
34. S.D. Henry, H.J. Metselaar, and R.C. Lonsdale Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-α Gastroenterology 131 2006 1452
35. M. Nakagawa, N. Sakamoto, and N. Enomoto Specific inhibition of hepatitis C virus replication by cyclosporin A Biochem Biophys Res Commun 313 2004 42
36. M. Wawrzynowicz-Syczewska, E. Herman, and K. Jurczyk Does cyclosporine inhibit in vivo hepatitis virus replication?a pilot study Transpl Int 20 2007 808
37. G. Levy, L.B. Lilly, and D.R. Grant The impact of calcineurin inhibitors (CNIs) on recurrent hepatitis C infection Am J Transplant 3 suppl 8 2004 410
38. M. Charlton Recurrence of hepatitis C infection: where are we now? Liver Transpl 11 11 suppl 2 2005 S57
39. G.V. Papatheodoridis, S.G. Barton, and D. Andrew Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens Gut 45 1999 427
40. L.B. Lilly, N. Selzner, and P. Wong Choice of CNI as well as genotype influence response to antiviral therapy in liver transplant recipients treated for recurrent HCV Am J Transplant 7 suppl 2 2007 Abst 14
41. K. Hirano, T. Ichikawa, and K. Nakao Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin A, on interferon-induced antiviral protein in human hepatocyte cells Liver Transpl 14 2008 292
42. K. Watashi, H.J. Metselaar, and L.J. van der Laan Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence Liver Transpl 14 2008 265
43. Q. Pan, H.J. Metselaar, and P. de Ruiter Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha Liver Transpl 16 2010 520
44. M. Guido, M. Rugge, and G. Leandro Hepatic stellate cell immunodetection and cirrhotic evolution of viral hepatitis in liver allografts Hepatology 26 1997 310
45. L. Cisneros, M.C. Londoo, and C. Blasco Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C Liver Transpl 13 2007 1017
46. M.W. Russo, R.J. Firpi, and D.R. Nelson Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C Liver Transpl 11 2005 1235
47. G. Carpino, S. Morini, and S. Ginanni Corradini Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation Dig Liver Dis 37 2005 349
48. H. Ikeda, and K. Fujiwara Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro Hepatology 21 1995 1161
49. M. Nakamuta, M. Kohjima, and M. Fukushima Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells Transpl Proc 37 2005 4598
50. M. Kohjima, M. Enjoji, and N. Higuchi NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells Liver Int 27 2007 1273